Calosens
About Calosens
Calosens is developing an analytical device for the in-vitro-diagnostics market that allows to analyse probes much faster, more sensitive (+/- 3nW) and more specific. In cases of bacterial infections (Meningitis/Sepsis) there is still a high mortality rate of up to 30% as the adequate medication and dose can not be appointed fast enough. This will improve with our device resulting in higher survival rates and reducing the risks of building new antibiotic resistance.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $9.9K
- Last round: Grant (Sep 2010)
- Website: calosens.com
Industries & Categories
Analytics
Social Profiles
Canonical: https://fsome.com/organization/calosens-899016 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.